Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial
- 10 June 2010
- journal article
- research article
- Published by Springer Nature in Osteoporosis International
- Vol. 22 (2) , 567-576
Abstract
Findings from this 5-year phase 3 study of postmenopausal women with osteoporosis showed that bazedoxifene was associated with an overall favorable safety and tolerability profile, with no evidence of endometrial or breast stimulation. Overall, the results at 5 years were consistent with those seen at 3 years.Keywords
This publication has 28 references indexed in Scilit:
- Bazedoxifene, a selective estrogen receptor modulatorMenopause, 2009
- Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosisMenopause, 2009
- Designing the ideal selective estrogen receptor modulator-an achievable goal?Menopause, 2009
- Effects of Bazedoxifene on BMD and Bone Turnover in Postmenopausal Women: 2-Yr Results of a Randomized, Double-Blind, Placebo-, and Active-Controlled StudyJournal of Bone and Mineral Research, 2008
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA, 2006
- Management of osteoporosis in postmenopausal womenMenopause, 2006
- Burden of OsteoporosisClinical Orthopaedics and Related Research, 2006
- Safety and Adverse Effects Associated With Raloxifene: Multiple Outcomes of Raloxifene EvaluationObstetrics & Gynecology, 2004
- The search for the ideal SERMExpert Opinion on Pharmacotherapy, 2002
- Epidemiology of Osteoporotic FracturesHormone Research in Paediatrics, 2000